Quiz|Articles|March 16, 2025
NeurologyLive® Brain Games: March 16, 2025
Author(s)Marco Meglio
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on gene therapy for neuromuscular disorders.
Advertisement
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topics, written by physicians, clinicians, and experts in the fields of neurological care and advocacy.
Test your mettle each week with 3 questions that cover a variety of aspects in the field of neurology, with a focus on dementia and Alzheimer disease, epilepsy and seizure disorders, headache and migraine, movement disorders, multiple sclerosis, neuromuscular disorders, sleep disorders, and stroke and cerebrovascular disease.
This week's questions include the theme of gene therapy for neuromuscular disorders.
Interested in submitting quiz questions? Contact our editor, Marco Meglio, via email: mmeglio@neurologylive.com .
Which genetic disorder is currently treated with the FDA-approved gene therapy onasemnogene abeparvovec?
What is the primary delivery vector used in most current gene therapies for neuromuscular disorders?
What is the main limitation of AAV-based gene therapy in neuromuscular disorders?
How did you do on this week's quiz? Let us know with a response to the poll below. Don't forget to share and compare your results with your friends!
How many questions did you get correct?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- NeurologyLive® Brain Games: September 14, 2025
September 14th 2025
- NeurologyLive® Friday 5 — September 12, 2025
September 12th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
2
Expanding the Alzheimer Drug Development Pipeline
3
Shared Decision-Making and Ethics in Complex Neurology Clinical Research: Paul Ford, PhD
4
DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point
5